Direct answers

What this exact search can and cannot establish.

Each answer stays attached to the compound identity and destination records. This is a verification guide, not medical or legal advice, a seller recommendation, or proof of availability.

01

What does a search for CagriSema in New Zealand need to establish?

CagriSema is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.

02

Which official records should be checked for CagriSema in New Zealand?

Resolve the exact identity of CagriSema through REDEFINE 1 Phase 3 study - NCT05567796 from ClinicalTrials.gov. Then search Unapproved peptide products health warning from New Zealand Medicines and Medical Devices Safety Authority for the destination product record and Product and application search from New Zealand Medicines and Medical Devices Safety Authority for the seller, establishment, or supply route in New Zealand. A match in one record does not replace the other two checks.

03

Does an online listing prove CagriSema is authorized or available in New Zealand?

No. A page using the name CagriSema, local currency, a domestic delivery claim, or a familiar package image is only a lead. This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status. For New Zealand, the exact product, presentation, seller identity, current record status, and claimed supply route must resolve through the official sources on this page.

Live trial footprint

CagriSema clinical trials in New Zealand

The current registry snapshot contains no CagriSema study record with a listed New Zealand location. This is a dated search result, not proof that a study cannot be added later.

Registry update: 24 July 2026
Study records
0
Listed locations
0
Recruiting locations
0
Records with local recruiting sites
0
0

The current registry snapshot contains no CagriSema study record with a listed New Zealand location. This is a dated search result, not proof that a study cannot be added later.

ClinicalTrials.gov search
Continue the exact comparison

Related country and compound records.

Compare another tracked name in New Zealand, or keep CagriSema fixed and change the destination within Asia-Pacific. The identity, product, and seller checks remain separate.

Continue the exact comparison

CagriSema in Asia-Pacific

CagriSema across 42 countries
Identity before availability

A name alone cannot establish a local verdict.

CagriSema is an investigational clinical program. No seller listing in New Zealand can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.

Primary identity source: REDEFINE 1 Phase 3 study - NCT05567796 / ClinicalTrials.gov
Three-record verification path

Identity. Product. Seller or supply.

A credible result must keep these separate. The official links answer different questions and should be checked in sequence.

REDEFINE 1 Phase 3 study - NCT05567796

REDEFINE 1 Phase 3 study - NCT05567796 is maintained by ClinicalTrials.gov. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open REDEFINE 1 Phase 3 study - NCT05567796

Unapproved peptide products health warning

Unapproved peptide products health warning is maintained by New Zealand Medicines and Medical Devices Safety Authority. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Unapproved peptide products health warning

Product and application search

Product and application search is maintained by New Zealand Medicines and Medical Devices Safety Authority. Open the current record and match the exact name, holder, presentation, legal entity, status, or route relevant to the claim.

Open Product and application search
New Zealand / Country guide

New Zealand market context.

New Zealand now has a peptide-specific Medsafe advisory that directly addresses online claims, unapproved products, research-purpose labels, and retatrutide. That warning must be checked before any product, seller, import, or price comparison.

  • Medsafe's May 2026 warning says research-purpose wording does not make an unapproved product legal or safe and identifies several names promoted online.
  • The Product/Application Search is the official route for checking products that have consent to be marketed in New Zealand.
  • The pharmacy register is updated separately and identifies licensed operators and premises, so seller and product checks must remain distinct.
Destination checklist

Repeat the country checks before comparing any offer.

The country guide supplies the local verification sequence. It does not convert an online listing into an authorized product or verified seller.

01

Read the current peptide advisory

Start with Medsafe's 21 May 2026 consumer advisory because it addresses unapproved peptide products, online promotion, research-purpose wording, and retatrutide specifically.

02

Search the product record

Use Medsafe's Product/Application Search to determine whether the exact product has consent to be marketed in New Zealand; a similar ingredient name is not a matching product record.

03

Verify the pharmacy separately

Use the Pharmacy Licence Register to match the legal entity, trading name, premises, and region. A product search does not verify the seller, and a pharmacy record does not approve every offer.

Primary evidence

Audit every source used by this page.

Open the live record and confirm its current status. A linked source begins the verification process; it does not mean Peptide Local authenticated a product or seller.

Audit and handoff

Keep the exact record attached.